Infectious Disease Advisor news story
Switching to long-acting antiretroviral therapy (ART) with cabotegravir (CAB) plus rilpivirine (RPV) does not appear to increase risk for hepatitis B virus (HBV) reactivation or incident infection in patients with HIV. However, pre-switch risk assessment and continued monitoring are advised in the setting of chronic HBV. These study findings were published in Clinical Infectious Diseases.
CAB/RPV does not have activity against HBV, raising concerns about viral reactivation or new infection in individuals with prior exposure or incomplete immunity. Evidence addressing this risk in routine clinical practice has remained limited.
Researchers in Spain conducted a prospective cohort study of adults with HIV who initiated long-acting CAB/RPV at Hospital Clínic Barcelona between February…